DOCSLIB.ORG

Topiroxostat Showed Renoprotection Via Various Mechanisms Including

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topiroxostat Showed Renoprotection Via Various Mechanisms Including Research Article iMedPub Journals Journal of Clinical & Experimental Nephrology 2016 http://www.imedpub.com/ Vol.1 No.4:24 ISSN 2472-5056 DOI: 10.21767/2472-5056.100024 Topiroxostat Showed Renoprotection via Various Mechanisms Including Suppression of Xanthine Oxidoreductase-Induced-Oxidative Stress and Inflammation in db/db Mice Takashi Nakamura1*, Goshi Nagao1, Mai Nampei1, Takayo Murase2, Nobutaka Morimoto1, Naoki Ashizawa3, Takashi Iwanaga3 and Ryusuke Sakamoto4 1Pharmacological Study Group, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan 2Radioisotope and Chemical Analysis Center, Sanwa Kagaku Kenkyusho, Mie, Japan 3Biological Research Group, Research Department, Medical R&D Division, Fuji Yakuhin, Saitama, Japan 4Project Management Department, Sanwa Kagaku Kenkyusho, Aichi, Japan *Corresponding author: Takashi Nakamura, Pharmacological Study Group, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho, Mie, 5110406, Japan, Tel: +81594726221; E-mail: [email protected] Received date: December 06, 2016; Accepted date: December 20, 2016; Published date: December 28, 2016 Citation: Nakamura T, Nagao G, Nampei M, Murase T, Morimoto N, et al. (2016) Topiroxostat Showed Renoprotection via Various Mechanisms Including Suppression of Xanthine Oxidoreductase-Induced-Oxidative Stress and Inflammation in db/db Mice. J Clin Exp Nephrol 1: 24. DOI: 10.21767/2472-5056.100024 Copyright: © 2016 Nakamura T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. relative to the vehicle. Moreover, febuxostat upregulated the gene expression of renin 1 (Ren1) and downregulated Abstract that of adenine phosphoribosyltransferase (APRT) and hypoxanthine guanine phosphoribosyltransferase (HPRT) Background: Xanthine oxidoreductase (XOR) produces compared with that of the diabetic control. superoxide along with uric acid. This reactive oxygen species induces organ damage. Therefore, we aimed to investigate Conclusion: Topiroxostat and febuxostat exhibited whether XOR-induced superoxide is associated with renal renoprotective effects by suppressing oxidative stress and abnormality in diabetic mice. inflammation, and enhancing the salvage pathway via XOR inhibition. Methods: Db/db mice (9-week-old) were fed standard diets with or without topiroxostat (1, 3, and 10 mg/kg/day) or febuxostat (3, 10, 30, and 45 mg/kg/day) for 4 weeks. Keywords: Topiroxostat; Xanthine oxidoreductase; Furthermore, topiroxostat (1 and 3 mg/kg/day) and Diabetic nephropathy; Albuminuria; Salvage pathway; Oxidative febuxostat (3 mg/kg/day) were administered for 7 days or 8 stress weeks. The levels of urinary albumin excretion (UAE), monocyte chemoattractant protein-1 (MCP-1), and angiotensin II were determined. For renal pathological or Introduction mechanistic analysis, periodic acid-Schiff (PAS), nitrotyrosine, and MCP-1 staining or renal gene expression, Xanthine oxidoreductase (XOR) is the rate-limiting enzyme XOR activity, and purine body levels were evaluated. that catalyzes the hydroxylation step in the conversion of hypoxanthine to xanthine and xanthine to uric acid (UA) in Results: Both topiroxostat and febuxostat suppressed UAE : purine metabolism [1,2]. Furthermore, this process can topiroxostat 3 mg/kg/day, 11.5 ± 33 μg/day versus vehicle simultaneously produce UA and reactive oxygen species (ROS) in 253.7 ± 69 μg/day, p<0.05; febuxostat 3 mg/kg/day, 255 ± 92 μg/day versus vehicle 634 ± 101 μg/day, p=0.05, for 4 vivo [1,2]. ROS-induced oxidative stress is considered a common weeks, respectively, and reduced immunohistological pathologic factor, leading to microvascular complications such as staining of enhanced oxidative stress and inflammation diabetic nephropathy, atherosclerosis, and hypertension [3-6], markers without affecting glycated hemoglobin. which cause albuminuria via vascular endothelial cell Topiroxostat but not febuxostat decreased urinary MCP-1 dysfunction [7]. Increased urinary albumin indicates a risk of and angiotensin II levels and attenuated morphological nephropathy progression in patients with diabetes [8] or hypertrophy in the glomerulus and epithelial cell cardiovascular events in the prognosis of those with acute enlargement (diameter and height) in the proximal tubules. In the early stage, topiroxostat and febuxostat decreased myocardial infarction [9]. renal XOR activity in response to increased purine body XOR inhibitors such as allopurinol, febuxostat, and levels (topiroxostat 3 mg/kg/day, 2.25 ± 0.19 mg/g tissue, p=0.07; febuxostat 3 mg/kg/day, 2.34 ± 0.09 mg/g tissue, topiroxostat are well-known medicines for lowering urate levels. p<0.05 to vehicle 2.01 ± 0.12 mg/g tissue, for 7 days) Several studies have reported that allopurinol reduced © Under License of Creative Commons Attribution 3.0 License | This article is available from: http://dx.doi.org/10.21767/2472-5056.100024 1 Journal of Clinical & Experimental Nephrology 2016 ISSN 2472-5056 Vol.1 No.4:24 tubulointerstitial injury by lowering UA [10] and febuxostat and detected using high-performance liquid chromatography (Tosoh, topiroxostat had a renoprotective effect by attenuating Tokyo, Japan). Urinary creatinine, albumin, monocyte inflammatory and oxidative stress in an animal model of chemotactic protein-1 (MCP-1), vascular endothelial growth diabetes [11] and of adenine-induced renal injury [12], factor (VEGF), and angiotensin II were measured using creatinine respectively. Compared with that reported for placebo, M L-type Wako (Wako Pure Chemical Industries, Ltd., Osaka, topiroxostat has been shown to decrease the urinary albumin- Japan), mouse albumin enzyme-linked immunosorbent assay to-creatinine ratio (ACR) in patients with chronic kidney disease (ELISA) kit (Bethyl Laboratory, Montgomery, TX, USA), mouse C-C (stage 3) with hyperuricemia in clinical trial [13] and an animal motif chemokine ligand 2 (CCL2)/JE/MCP-1 Quantikine ELISA kit, model of diabetic nephropathy [14]. However, there are a few mouse VEGF Quantikine ELISA kit (both R&D Systems, reports that topiroxostat has protective effects on the kidneys. Minneapolis, MN, USA), and angiotensin II ELISA kit (Peninsula Therefore, in the present study, we aimed to investigate Laboratories, LLC, San Carlos, CA, USA), respectively. whether topiroxostat has renoprotective effects and provided insights into the difference in the effect of topiroxostat and Liver and renal XOR activity assay febuxostat. The XOR activity was measured according to the procedure reported previously [15]. In brief, the liver and kidney Material and Methods homogenates were centrifuged for 60 min at 105,000 ×g, 4°C. Topiroxostat, febuxostat, and [13C , 15N ]-UA were synthesized The cytosolic or plasma fractions were added to the reaction 2 2 15 in our laboratory while [15N ]-xanthine and [15N ]-UA were mixtures containing [ N2]-xanthine (60 nmol), nicotinamide 2 2 + purchased from Cambridge Isotope Laboratories (Tewksbury, adenine dinucleotide (NAD , 150 nmol), and oxonate (2.0 nmol). MA, USA). All other chemicals used were of molecular biology Tris-hydrochloride (HCl) buffer (pH 8.5) was then added to adjust grade. the total volume to 150 μL for each reaction mixture. These mixtures were incubated at 37°C for 30 min and then 50 μL 200 13 15 Animal studies μmol/L [ C2, N2]-UA was added as the internal standard (ISTD). Subsequently, the mixture was heated for 5 min at 95°C All the experimental protocols were approved by the to stop the reaction. The resulting suspensions were centrifuged Committee on Animal Care of Sanwa Kagaku Kenkyusho. Male for 10 min at 15,000 × g at 4°C. The supernatants were filtered db/db and their littermate db/lean (db/m) mice obtained from through an ultrafiltration membrane (Amicon® ultra-0.5 Charles River Japan (Osaka, Japan) at 8 weeks of age were fed centrifugal filter devices, 3K, Millipore) and the production levels 15 laboratory standard powder chow, CRF-1 (Oriental Yeast Co., of [ N2]-UA were determined using liquid chromatography/ Ltd., Tokyo, Japan). The mice were allowed ad libitum access to mass spectrometry (LC/MS, linear trap quadrupole [LTQ]- food and water and were maintained in plastic cages at a Orbitrap, Thermo Fisher Scientific GmbH, Bremen, Germany). 15 constant temperature of 23 ± 2°C under a 12-h light-dark cycle Each activity was expressed as [ N2]-UA nmol. (lights on from 7:00 am to 7:00 pm). At 9 weeks of age, the diabetic mice were divided into four or five groups with matched Renal purine bodies concentrations body mass, food intake, urinary albumin excretion (UAE), and glycated hemoglobin (HbA1c) and treated as indicated in the The kidney tissue samples were homogenized in phosphate- following studies: study A, vehicle and topiroxostat treatment (1, buffered saline (PBS, pH 7.4) containing a protease inhibitor 3, and 10 mg/kg/day) for 4 weeks; study B, vehicle and cocktail (Roche, Basel, Switzerland) and centrifuged at 20,000 × febuxostat treatment (3, 10, 30, and 45 mg/kg/day) for 4 weeks; g at 4°C for 20 min. For the determination of hypoxanthine and and study C, vehicle and either drug (topiroxostat 1 and 3 xanthine, the homogenate was added to Tris buffer (pH 8.5) 15 15 mg/kg/day and febuxostat 3 mg/kg/day) for 7 days or 8 weeks. containing sodium chloride (NaCl), [ N2]-xanthine, and [ N2]- UA as the ISTD and then heated immediately at 95°C for 5 min. The
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics
    Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics Jamelle M. Simmons Dissertation submitted to the Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Engineering Yong W. Lee, Chair Luke E. Achenie Hampton C. Gabler Alexei Morozov Aaron S. Goldstein John H. Rossmeisl November 27, 2018 Blacksburg, Virginia Keywords: Autism Spectrum Disorder, Xanthine Oxidase, Reactive Oxygen Species, Pharmacokinetics, Animal Behavior Copyright 2019, Jamelle M. Simmons Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics Jamelle M. Simmons (ABSTRACT) Autism spectrum disorder (ASD) is a lifelong disability that has seen a rise in prevalence from 1 in 150 children to 1 in 59 between 2000 and 2014. Patients show behavioral ab- normalities in the areas of social interaction, communication, and restrictive and repetitive behaviors. As of now, the exact cause of ASD is unknown and literature points to multiple causes. The work contained within this dissertation explored the reduction of oxidative stress in brain tissue induced by xanthine oxidase (XO). Febuxostat is a new FDA approved XO- inhibitor that has been shown to be more selective and potent than allopurinol in patients with gout.The first study developed a computational model to calculate an effective diffu- sion constant (Deff ) of lipophilic compounds, such as febuxostat, that can cross endothelial cells of the blood-brain barrier (BBB) by the transcellular pathway. In the second study, male juvenile autistic (BTBR) mice were treated with febuxostat for seven days followed by behavioral testing and quantification of oxidative stress in brain tissue compared to controls.
    [Show full text]
  • ULORIC Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS-------------------­ These highlights do not include all the information needed to use ULORIC safely and effectively. See full prescribing • Cardiovascular Death: In a CV outcomes study, there was a higher information for ULORIC. rate of CV death in patients treated with ULORIC compared to allopurinol; in the same study ULORIC was non-inferior to ULORIC (febuxostat) tablets, for oral use allopurinol for the primary endpoint of major adverse Initial U.S. Approval: 2009 cardiovascular events (MACE). Consider the risks and benefits of WARNING: CARDIOVASCULAR DEATH ULORIC when deciding to prescribe or continue patients on See full prescribing information for complete boxed warning. ULORIC. (1, 5.1) • Gout patients with established cardiovascular (CV) disease • Gout Flares: An increase in gout flares is frequently observed treated with ULORIC had a higher rate of CV death compared to during initiation of anti-hyperuricemic agents, including ULORIC. If those treated with allopurinol in a CV outcomes study. (5.1) a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti- • Consider the risks and benefits of ULORIC when deciding to inflammatory drug [NSAID] or colchicine upon initiation of prescribe or continue patients on ULORIC. ULORIC should only treatment) may be beneficial for up to six months. (2.4, 5.2) be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to • Hepatic Effects: Postmarketing reports of hepatic failure, allopurinol, or for whom treatment with allopurinol is not sometimes fatal. Causality cannot be excluded.
    [Show full text]
  • Gouric Insert Final
    Dosage Recommendations in Patients with Renal Impairment and Hepatic are at risk for severe drug-induced liver injury and should not be restarted on febuxostat. Impairment For patients with lesser elevations of serum ALT or bilirubin and with an alternate USE IN SPECIAL POPULATIONS No dose adjustment is necessary when administering Gouric in patients with mild or probable cause, treatment with febuxostat can be used with caution. moderate renal impairment. Pregnancy The recommended dosage of Gouric is limited to 40 mg once daily in patients with severe Thyroid disorders US FDA Pregnancy Category C. There are no adequate and well-controlled studies in renal impairment. Increased TSH values (>5.5 μIU/mL) were observed in patients on long-term treatment pregnant women. Febuxostat should be used during pregnancy only if the potential No dose adjustment is necessary in patients with mild to moderate hepatic impairment. with febuxostat (5.5%) in the long term open label extension studies. Caution is required benefit justifies the potential risk to the fetus. when febuxostat is used in patients with altered of thyroid function. Uric Acid Level Nursing mother COMPOSITION Testing for the target serum uric acid level of less than 6 mg/dL may be performed as early Effects on ability to drive and use machines Febuxostat is excreted in the milk of rats. It is not known whether this drug is excreted in Gouric® 40mg Tablet as two weeks after initiating Gouric therapy. Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of human milk. Because many drugs are excreted in human milk, caution should be Each film-coated tablet contains: Febuxostat.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0059868 A1 Miner Et Al
    US 2013 0059868A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0059868 A1 Miner et al. (43) Pub. Date: Mar. 7, 2013 (54) TREATMENT OF GOUT Publication Classification (75) Inventors: Jeffrey Miner, San Diego, CA (US); Jean-Luc Girardet, San Diego, CA (51) Int. Cl. (US); Barry D. Quart, Encinitas, CA A613 L/496 (2006.01) (US) A6IP 29/00 (2006.01) (73) Assignee: Ardea Biociences, Inc., San Diego, CA A6IP 9/06 (2006.01) (US) A613 L/426 (2006.01) A 6LX3/59 (2006.01) (21) Appl. No.: 13/637,343 (52) U.S. Cl. ...................... 514/262.1: 514/384: 514/365 (22) PCT Fled: Mar. 29, 2011 (86) PCT NO.: PCT/US11A3O364 (57) ABSTRACT S371 (c)(1), (2), (4) Date: Oct. 24, 2012 Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H Related U.S. Application Data 1,2,4-triazol-3-ylthio)acetate is described. In addition, phar (60) Provisional application No. 61/319,014, filed on Mar. maceutical compositions and uses Such compositions for the 30, 2010. treatment of a variety of diseases and conditions. Patent Application Publication Mar. 7, 2013 Sheet 1 of 10 US 2013/00598.68A1 FIGURE 1 S. C SOC 55000 40 S. s 3. s Patent Application Publication Mar. 7, 2013 Sheet 2 of 10 US 2013/00598.68A1 ~~~::CC©>???>©><!--->?©><??--~~~~~·%~~}--~~~~~~~~*~~~~~~~~·;--~~~~~~~~~;~~~~~~~~~~}--~~~~~~~~*~~~~~~~~;·~~~~~ |×.> |||—||--~~~~ ¿*|¡ MSU No IL-1ra MSU50 IL-1ra MSU 100 IL-1ra MSU500 IL-1ra cells Only No IL-1 ra Patent Application Publication Mar. 7, 2013 Sheet 3 of 10 US 2013/00598.68A1 FIGURE 3 A: 50000 40000 R 30000 2 20000 10000 O -7 -6 -5 -4 -3 Lesinurad (log)M B: Lesinurad (log)M Patent Application Publication Mar.
    [Show full text]
  • Azathioprine-Induced Severe Anemia Potentiated by the Concurrent Use Of
    PRACTICE | CASES CPD Azathioprine-induced severe anemia potentiated by the concurrent use of allopurinol Lorenzo Madrazo MD, Emily Jones MD, Cyrus C. Hsia MD n Cite as: CMAJ 2021 January 18;193:E94-7. doi: 10.1503/cmaj.201022 66-year-old man presented to the emergency depart- ment with a 2-week history of progressive weakness and KEY POINTS lethargy. Three months before presentation, he had • Severe anemia and myelosuppression are rare but serious beenA started on azathioprine therapy for immunoglobulin (Ig) complications of azathioprine that are more likely to occur at G4-related biliary disease. Comorbidities included hypertension, high doses or when potentiated by interactions with other peripheral vascular disease, type 2 diabetes mellitus, salivary drugs. gland fibrosis, hypothyroidism, gastresophageal reflux disease, • Xanthine oxidase inhibitors such as allopurinol or febuxostat hyperlipidemia, osteoarthritis and gout. The patient was taking increase the production of myelotoxic metabolites from azathioprine. azathioprine 200 mg once daily and had been taking allopurinol 100 mg once daily for several years to manage his gout. Other • Initiation of azathioprine should be accompanied by regular monitoring of a complete blood count with differential and liver medications included sitagliptin 100 mg once daily, gliclazide enzymes at least every 2 weeks during initial dose titration, and, 120 mg once daily, acetylsalicylic acid 81 mg once daily, once stable, at least every 3 months thereafter, as clinically extended-release metoprolol 200 mg once daily, ramipril 5 mg appropriate. once daily, atorvastatin 40 mg once daily, rabeprazole 20 mg twice daily, clonazepam 2 mg at bedtime, gabapentin 100 mg 3 times daily, venlafaxine 225 mg daily, vitamin D 1000 IU once Investigations for anemia included upper and lower endos- daily and ibuprofen 800 mg as needed.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease (TROFEO Trial)
    Circ J 2017; 81: 1707 – 1712 ORIGINAL ARTICLE doi: 10.1253/circj.CJ-17-0438 Preventive Medicine Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial) Akira Sezai, MD, PhD; Kazuaki Obata; Keisuke Abe; Sakie Kanno; Hisakuni Sekino, MD, PhD Background: We previously reported that febuxostat was more effective for hyperuricemia than allopurinol. The efficacy, however, of topiroxostat (a novel xanthine oxidase reductase inhibitor similar to febuxostat), for hyperuricemia is unknown. Methods and Results: Patients with cardiovascular disease and hyperuricemia, in whom serum uric acid (s-UA) was controlled at ≤6 mg/dL, were eligible for enrollment. Fifty-five patients were randomized to receive either febuxostat or topiroxostat for 6 months and were switched to the other drug for the following 6 months. The primary endpoint was s-UA. Secondary endpoints included serum creatinine, estimated glomerular filtration rate, urinary albumin, cystatin-C, oxidized low-density lipoprotein, eicosapentaenoic acid/ arachidonic acid ratio, lipid biomarkers, high-sensitivity C-reactive protein and B-type natriuretic protein. Although s-UA level was similar for both drugs, significantly more patients required dose escalation during treatment with topiroxostat. There were no differ- ences in renal function, inflammatory and lipid markers between the 2 drugs. A biomarker of oxidative stress was significantly lower after 3 months of febuxostat compared with topiroxostat. Conclusions: Febuxostat causes more marked and more rapid reduction of s-UA than topiroxostat. With regard to the antioxidant effect, febuxostat was superior to topiroxostat after 3 months. The renal protective and anti-inflammatory effects of both drugs were also similar after 6 months of treatment.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]